B+
Bull case
25%
Probability
Target price
$0.55
+174.7% vs current
GOSS
Gossamer BioBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$0.34
+69.8% vs current
B-
Bear case
30%
Probability
Target price
$0.16
-20.1% vs current
AI sentiment snapshot
Latest data as of 2026-05-16
Recent news sentiment (30D)
-0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+100.0
Score
AI commentary
Tone remains cautious and tentative. Primary-source evidence is real, but the setup is still mostly a monitoring story centered on post-PROSERA regulatory salvage and runway management. The May 15, 2026 earnings follow-up looks mixed: consensus-tracker data flagged an EPS miss and revenue beat, while the stock reaction was muted-to-slightly positive into a $0.34 close, suggesting limited fresh conviction either way. Clear analyst target revisions, broad post-print estimate changes, and a direct peer set were not available as of May 16, 2026, so those gaps should lower confidence rather than be read positively.
RankAlpha Sentiment Codex - 2026-05-16
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-18catalystPost-earnings digestion remains mixed rather than thesis-changingHigh impact
The Q1 2026 10-Q was filed on May 15, 2026, and third-party earnings trackers showed an EPS miss against consensus but a large revenue beat; shares still closed at $0.34 on May 15, up about 3%, implying the tape is reacting more to survival and regulatory optionality than to quarterly P&L alone [#10-Q-2026-05-15].
2026-06-30eventFDA path-forward discussion is the key near-term rerating eventHigh impact
After PROSERA missed its prespecified primary-endpoint alpha threshold, company materials said seralutinib still showed activity in higher-risk patients and that Gossamer planned a Type C FDA meeting potentially in June 2026 while SERANATA enrollment remained paused. A credible regulatory path would matter far more than quarterly financial noise, but visibility is still weak.
2026-12-31catalystRunway and financing terms will increasingly shape equity outcomesHigh impact
The March 31, 2026 10-Q said Gossamer had $99.2 million of cash, cash equivalents and marketable securities and believed that was enough into Q1 2027, but it also explicitly said existing cash and cash equivalents were not sufficient for at least one year and raised substantial doubt about going concern, keeping dilution and financing structure as major long-horizon drivers [#10-Q-2026-05-15].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-16 • Updated nightlySource: Internal modelMethodology